Latest Content

RAMPART shows early quality-of-life declines with adjuvant Imfinzi and Imjudo, improving over time, though later cognitive and pain effects emerge.

Living long-term with cancer means learning to live in chapters. There are calm chapters and uncertain ones. Seasons of stability and seasons of intervention.

Four new and ongoing lung cancer trials are enrolling patients, offering options in first-line and previously treated NSCLC settings.

Phase 2 INDIBLADE data support Yervoy and Opdivo before bladder-sparing chemoradiotherapy.

Keytruda plus paclitaxel improved overall survival by 18% in platinum-resistant ovarian cancer in the phase 3 KEYNOTE-B96 trial.

Overview of nodular sclerosis Hodgkin lymphoma, including diagnosis, staging, treatment options by stage and possible side effects.

Keytruda/Welireg and Welireg/Lenvima combinations show improved survival and disease control in kidney cancer, according to new data from ASCO GU.

Keytruda plus Welireg lowered the risk of recurrence in high-risk clear cell kidney cancer after surgery.

Welireg plus Lenvima improved outcomes compared with versus Cabometyx in advanced clear cell renal cell carcinoma after immunotherapy.

Day two of ASCO GU highlighted innovative therapies and the need for better quality-of-life reporting in genitourinary cancer trials.

Disitamab vedotin demonstrated responses in previously treated HER2-expressing advanced urothelial carcinoma, with activity across HER2 expression levels.

Adding cabazitaxel to hormone therapy and radiation did not improve survival and caused more side effects in high-risk localized prostate cancer.

Padcev plus Keytruda before and after surgery helped more bladder cancer patients live longer and remain cancer-free than standard chemotherapy.